251 related articles for article (PubMed ID: 17681665)
1. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
Bueno C; Lopes LF; Greaves M; Menendez P
Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
[No Abstract] [Full Text] [Related]
2. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Mitsiades CS; Mitsiades NS; Bronson RT; Chauhan D; Munshi N; Treon SP; Maxwell CA; Pilarski L; Hideshima T; Hoffman RM; Anderson KC
Cancer Res; 2003 Oct; 63(20):6689-96. PubMed ID: 14583463
[TBL] [Abstract][Full Text] [Related]
3. [Plasmocytic pleural effusion disclosing multiple myeloma].
Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
5. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
Calimeri T; Battista E; Conforti F; Neri P; Di Martino MT; Rossi M; Foresta U; Piro E; Ferrara F; Amorosi A; Bahlis N; Anderson KC; Munshi N; Tagliaferri P; Causa F; Tassone P
Leukemia; 2011 Apr; 25(4):707-11. PubMed ID: 21233838
[No Abstract] [Full Text] [Related]
6. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
7. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
9. The SCID-hu myeloma model.
Epstein J; Yaccoby S
Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
[TBL] [Abstract][Full Text] [Related]
10. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
[TBL] [Abstract][Full Text] [Related]
11. Characterization of in vitro growth of multiple myeloma cells.
Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma-initiating cells.
Hosen N
Int J Hematol; 2013 Mar; 97(3):306-12. PubMed ID: 23420183
[TBL] [Abstract][Full Text] [Related]
13. [Preleukemic states: an experimental murine model for myelodysplastic human syndromes].
Defresne MP
Bull Mem Acad R Med Belg; 2001; 156(1-2):99-104; discussion 105-6. PubMed ID: 11697189
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting the in vitro evolution of a myeloma cell line.
Scibienski RJ; Paglieroni T; Caggiano V; Lemongello D; Gumerlock PH; Mackenzie MR
Leukemia; 1992 Sep; 6(9):940-7. PubMed ID: 1518305
[TBL] [Abstract][Full Text] [Related]
15. IgM multiple myeloma: more on a rare and heterogeneous disease.
Cabrera Q; Chantepie S; Salaun V; Levaltier X; Troussard X; Macro M
Am J Hematol; 2011 Aug; 86(8):717-8; author reply 718-9. PubMed ID: 21630314
[No Abstract] [Full Text] [Related]
16. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
[TBL] [Abstract][Full Text] [Related]
17. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
18. Defining IgM multiple myeloma.
Owen RG; Feyler S; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
Am J Hematol; 2011 Aug; 86(8):717; author reply 718-9. PubMed ID: 21761439
[No Abstract] [Full Text] [Related]
19. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
20. Biology and bioinformatics of myeloma cell.
Abroun S; Saki N; Fakher R; Asghari F
Lab Hematol; 2012 Dec; 18(4):30-41. PubMed ID: 23253865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
